Citation Information :
Alwani H, Subhankar S, Rao CM, Kar S, Kumar S, Bal HB, Das D, Dash DP. Role of CBNAAT in the Diagnosis of Extra-Pulmonary Tuberculosis: Experience from a Tertiary Care Hospital in India. Indian J Chest Dis Allied Sci 2022; 64 (1):9-14.
Background. Xpert-MTB/RIF assay or Cartridge-Based Nucleic Acid Amplification Test (CBNAAT) helps in rapid diagnosis of tuberculosis (TB).
Methods. Specific samples were collected and carried to Regional Medical Research Centre where these were taken up for CBNAAT and culture in Lowenstein-Jensen media. Appropriate samples were sent to the Designated Microscopy Centre (DMC) of our institute for acid-fast bacilli (AFB) smear examination. Diagnostic measures, such as sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy of Xpert-MTB/RIF were reported considering mycobacterial culture and a composite reference standard (CRS) as Gold standard.
Results. We studied 335 samples. Lymph node fine needle aspirate was the most common sample (32.5%) followed by pleural fluid (29.3%). The overall sensitivity and specificity of Xpert-MTB/RIF was determined to be 26.5% (95% CI [confidence interval] 20.8–32.8) and 100% (95% CI 96.8–100), respectively. The sensitivity and specificity of CBNAAT in relation to mycobacterial culture, however, was 78.8% (95% CI 61.1–91.0) and 89.1% (95% CI 85–92.4), respectively. Both were highest for pus, cerebrospinal fluid and lymph node fine needle aspirate samples.
Conclusions. Xpert-MTB/RIF may be useful for samples, like cold abscess and lymph node fine needle aspirate or biopsy specimens. However, its routine use in case of serosal fluids is not recommended because of its lower sensitivity.
India M. TB India Report 2018. Ministry of Health and Family Welfare [Internet]. Tbcindia.gov.in. 2020 [cited 21 December 2020]. Available from URL: https://tbcindia.gov.in/showfile.php?lid=3314. Accessed on July 20, 2019.
Global Tuberculosis Control 2009 - Epidemiology Strategy Financing - World [Internet]. ReliefWeb. 2020 [cited 21 December 2020]. Available from URL: https://reliefweb.int/report/world/global-tuberculosis-control-2009-epidemiology-strategy-financing. Accessed on July 21, 2019.
Gallant V, Ogunnaike-Cooke S, McGuire M. Tuberculosis in Canada: 1924-2012. Can Commun Dis Rep 2014;20;40:99–107. doi: 10.14745/ccdr.v40i06a02.
India M. Index-TB guidelines:: Ministry of Health and Family Welfare [Internet]. Tbcindia.gov.in. 2020 [cited 21 December 2020]. Available from URL: https://tbcindia.gov.in/showfile.php?lid=3245. Accessed on July 22, 2019.
Organization W. Global tuberculosis report 2018 [Internet]. Apps.who.int. 2020 [cited 21 December 2020]. Available from URL: https://apps.who.int/iris/handle/10665/274453. Accessed on July 25, 2019.
Prakasha S, Suresh G, Shetty S, D′sa I, Kumar S. Mapping the pattern and trends of extrapulmonary tuberculosis. J Global Infect Dis 2013;5:54.
Shrivastava D, Brahmachari D, Pathak D, Kumar D, Sainia D, Patel D, et al. Clinico-epidemiological profile of extra-pulmonary tuberculosis in Central India. Int J Med Res Rev 2015;3:223–30.
Ohene S, Bakker M, Ojo J, Toonstra A, Awudi D, Klatser P. Extra-pulmonary tuberculosis: a retrospective study of patients in Accra, Ghana. PLoS One 2019;14:e0209650.
Connolly M, Nunn P. Women and tuberculosis. World Health Stat Q1996;49:115–9.
Velingker A, Lawande D, Dcosta L. Clinico-epidemiological profile of extrapulmonary tuberculosis in Western India. Int J Contemp Med Res 2018;5:B1–B4.
Gaur P, Suryakant S, Bhaskar R, Singh S, Saxena P, Agnihotri S. Incidence and clinical profiles of pulmonary and extra-pulmonary tuberculosis patients in North Indian population: a hospital based retrospective study. Int J Res Develop Pharm Life Sci 2017;6:2773–8.
Denkinger C, Schumacher S, Boehme C, Dendukuri N, Pai M, Steingart K. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. Eur Respir J 2014;44:435–46.
Maynard-Smith L, Larke N, Peters J, Lawn S. Diagnostic accuracy of the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis when testing non-respiratory samples: a systematic review. BMC Infect Dis 2014;14:709. doi: 10.1186/s12879-014-0709-7.
Sharma SK, Kohli M, Chaubey J, Yadav RN, Sharma R, Singh BK, et al. Evaluation of Xpert MTB/RIF assay performance in diagnosing extrapulmonary tuberculosis among adults in a tertiary care centre in India. Eur Respir J 2014;44:1090–3.
Lawn S, Zumla A. Diagnosis of extrapulmonary tuberculosis using the Xpert®MTB/RIF assay. Expert Rev Anti-Infect Therapy 2012;10:631–5.
Tortoli E, Russo C, Piersimoni C, Mazzola E, Dal Monte P, Pascarella M, et al. Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. Eur Respir J 2012;40:442–7.
Hillemann D, Rusch-Gerdes S, Boehme C, Richter E. Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. J Clin Microbiol 2011;49:1202–5.
Vadwai V, Boehme C, Nabeta P, Shetty A, Alland D, Rodrigues C. Xpert MTB/RIF: a new pillar in diagnosis of extra pulmonary tuberculosis? J Clin Microbiol 2011;49:2540–5.